Declining Trend of Transapical Access for Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis

Table 2

Comorbidities of patients undergoing TAVR through transapical vs. nontransapical approaches.

	Non-TA-TAVR	TA-TAVR	value
Hypertension	52.19	74.15	0.0001
Type 2 DM	37.38	34.57	0.0109
Chronic ischemic heart disease	40.23	62.39	0.0001
Acute myocardial infarction	1.82	1.79	0.92
Dyslipidemia	67.48	66.4	0.37
Peripheral vascular disease	20.03	35.32	0.0001
Obesity	14.57	11.19	0.0001
Chronic kidney disease	35.16	33.13	0.12
ESRD	3.56	3.88	0.48
Atrial fibrillation	31.59	44.62	0.0001
Chronic liver disease	1.53	1.24	0.32
Chronic lung disease	32.87	42.79	0.0001
Smoking status	34.77	33.52	0.31
Alcohol consumption	0.75	0.5	0.19